Arcutis Biotherapeutics reports Q3 EPS 6c, consensus 17c
Arcutis Biotherapeutics reported Q3 EPS of 6c, below the 17c consensus, with revenue of $143.92M, slightly above the $142.59M consensus. The company highlighted strong performance and growth prospects, including a potential FDA approval for ZORYVE cream in early 2027 and ongoing clinical trials. CEO Frank Watanabe announced a new awareness campaign with Simone Biles to promote ZORYVE.
How this was made
The 30-second read
Why it matters
Earnings miss may trigger short‑term sell‑off, but upcoming FDA decisions and pipeline progress could provide longer‑term upside.
Market read
Arcutis' earnings miss is the primary catalyst for near‑term price action; investors will watch upcoming regulatory milestones.
What to watch
Potential FDA approval for ZORYVE cream in early 2027 and progress on ARQ-234 trial may offset short‑term earnings disappointment.
Background
Arcutis Biotherapeutics highlighted its ZORYVE product line and announced a new awareness campaign with Simone Biles.
Ticker impact
Q3 earnings report shows EPS of $0.06 versus consensus $0.17 and revenue $143.92M versus $142.59M, a miss on earnings that may pressure the stock.
likely pressure as the market prices in the earnings miss
The company missed consensus EPS by a wide margin; biotech stocks typically react sharply to earnings surprises.
Market effects
The miss may weigh on the broader dermatology biotech sector as investors compare pipelines.
Limited to US biotech investors; no broader regional effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
If the revenue beat is viewed as a sign of strong demand, the stock could rebound despite the EPS miss.
Key entities
- ExecutiveFrank Watanabe
President and CEO of Arcutis Biotherapeutics, provided commentary on earnings and pipeline.

